Our top pick for
Hawkins, Inc is a specialty chemicals business based in the US. Hawkins shares (HWKN) are listed on the NASDAQ and all prices are listed in US Dollars. Hawkins employs 656 staff and has a trailing 12-month revenue of around USD$566.3 million.
|52-week range||USD$26.3432 - USD$63.96|
|50-day moving average||USD$56.6174|
|200-day moving average||USD$52.2538|
|Wall St. target price||USD$67|
|Dividend yield||USD$0.93 (1.49%)|
|Earnings per share (TTM)||USD$3.439|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Hawkins stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Hawkins's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Hawkins's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Hawkins shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Hawkins's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$73.5 million.
The EBITDA is a measure of a Hawkins's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$566.3 million|
|Operating margin TTM||9.07%|
|Gross profit TTM||USD$101.5 million|
|Return on assets TTM||7.71%|
|Return on equity TTM||14.99%|
|Market capitalisation||USD$653.6 million|
TTM: trailing 12 months
There are currently 144,464 Hawkins shares held short by investors – that's known as Hawkins's "short interest". This figure is 7.5% up from 134,370 last month.
There are a few different ways that this level of interest in shorting Hawkins shares can be evaluated.
Hawkins's "short interest ratio" (SIR) is the quantity of Hawkins shares currently shorted divided by the average quantity of Hawkins shares traded daily (recently around 32536.936936937). Hawkins's SIR currently stands at 4.44. In other words for every 100,000 Hawkins shares traded daily on the market, roughly 4440 shares are currently held short.
However Hawkins's short interest can also be evaluated against the total number of Hawkins shares, or, against the total number of tradable Hawkins shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Hawkins's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Hawkins shares in existence, roughly 10 shares are currently held short) or 0.0181% of the tradable shares (for every 100,000 tradable Hawkins shares, roughly 18 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Hawkins.
Find out more about how you can short Hawkins stock.
Dividend payout ratio: 27.24% of net profits
Recently Hawkins has paid out, on average, around 27.24% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.57% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Hawkins shareholders could enjoy a 1.57% return on their shares, in the form of dividend payments. In Hawkins's case, that would currently equate to about $0.93 per share.
While Hawkins's payout ratio might seem fairly standard, it's worth remembering that Hawkins may be investing much of the rest of its net profits in future growth.
Hawkins's most recent dividend payout was on 26 February 2021. The latest dividend was paid out to all shareholders who bought their shares by 11 February 2021 (the "ex-dividend date").
Hawkins's shares were split on 25 March 1997.
Over the last 12 months, Hawkins's shares have ranged in value from as little as $26.3432 up to $63.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Hawkins's is 0.8623. This would suggest that Hawkins's shares are less volatile than average (for this exchange).
Hawkins, Inc. blends, manufactures, and distributes chemicals and other specialty ingredients in the United States and internationally. It operates through three segments: Industrial, Water Treatment, and Health and Nutrition. The Industrial segment offers industrial chemicals, products, and services to agriculture, chemical processing, electronics, energy, food, pharmaceutical, and plating industries. This segment primarily provides acids, alkalis, and industrial and food-grade salts. It also receives, stores, and distributes various chemicals in bulk quantities, such as liquid caustic soda, sulfuric acid, hydrochloric acid, urea, phosphoric acid, aqua ammonia, and potassium hydroxide. In addition, this segment manufactures sodium hypochlorite and agricultural products, as well as various food-grade products that include liquid phosphates, lactates, and other blended products; repackages water treatment chemicals and bulk industrial chemicals; and performs custom blending of chemicals, and contract and private label bleach packaging. The Water Treatment segment offers chemicals, equipment, and solutions for potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool and agriculture water. The Health and Nutrition segment offers ingredient distribution, processing, and formulation solutions to manufacturers of nutraceutical, functional food and beverage, personal care, dietary supplement and other nutritional food, and health and wellness products. Its products portfolio includes minerals, botanicals and herbs, vitamins and amino acids, excipients, joint products, sweeteners, and enzymes. The company was founded in 1938 and is headquartered in Roseville, Minnesota.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.